Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures

被引:66
作者
Sessink, PJM [1 ]
Wittenhorst, BCJ [1 ]
Anzion, RBM [1 ]
Bos, RP [1 ]
机构
[1] UNIV NIJMEGEN, FAC MED SCI, DEPT TOXICOL, NL-6500 HB NIJMEGEN, NETHERLANDS
来源
ARCHIVES OF ENVIRONMENTAL HEALTH | 1997年 / 52卷 / 03期
关键词
D O I
10.1080/00039899709602893
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
In the past, special guidelines and protective measures have been introduced to protect hospital workers during the handling of antineoplastic agents; nevertheless, it was found that they did not prevent the uptake of these toxic compounds. In response, additional protective measures were introduced, including adaptations of the laminar downflow hood, use of special masks, use of double pairs of gloves, and replacement of ampules with vials. In the current study, the authors compared the effects in these additional measures with results of a previous study. Cyclophosphamide, 5-fluorouracil, and methotrexate constituted 81% of the antineoplastic agents prepared; therefore, the investigators monitored these compounds again by personal air sampling and by determining the levels of contamination on masks and gloves. Cyclophosphamide in the urine of workers was also measured. During preparation, investigators concluded that there were lower concentrations of cyclophosphamide in the air than had occurred in the previous study. Replacement of ampules with vials (i.e., 5-fluorouracil) resulted in a significantly diminished contamination of latex gloves. Cyclophosphamide was detected in urine samples provided by six of nine technicians; the maximum amount excreted over 5 d was 2.6 mu g. The mean cyclophosphamide excretion/d was not significantly lower than that found in the previous study (0.16 mu g and 1.44 mu g, respectively). Despite an intensified hygienic regimen, exposure to antineoplastic agents cannot be reduced if the reasons for exposure remain unknown.
引用
收藏
页码:240 / 244
页数:5
相关论文
共 17 条
[1]  
[Anonymous], 1990, AM J HOSP PHARM, V47, P1033
[2]  
British Pharmaceutical Society, 1983, PHARM J, V1, P230
[3]  
*CAN SOC HOSP PHAR, 1981, CAN J HOSP PHARM JUL, P37
[4]  
ERIKSEN IL, 1982, PHARM INT, V3, P264
[5]   URINARY CYCLOPHOSPHAMIDE ASSAY AS A METHOD FOR BIOLOGICAL MONITORING OF OCCUPATIONAL EXPOSURE TO CYCLOPHOSPHAMIDE [J].
EVELO, CTA ;
BOS, RP ;
PETERS, JGP ;
HENDERSON, PT .
INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, 1986, 58 (02) :151-155
[6]  
HIRST M, 1984, LANCET, V1, P186
[7]  
*INT KANK, 1992, GUID ANT AG
[8]  
*INT KANK NOORD IN, 1986, GUID HANDL APPL ANT
[9]   DETECTION OF CONTAMINATION WITH ANTINEOPLASTIC AGENTS IN A HOSPITAL PHARMACY DEPARTMENT [J].
SESSINK, PJM ;
ANZION, RB ;
VANDENBROEK, PHH ;
BOS, RP .
PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1992, 14 (01) :16-22
[10]  
SESSINK PJM, 1994, J OCCUP ENVIRON MED, V36, P79